HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $390
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $380 to $390.
November 07, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vertex Pharmaceuticals' price target has been raised from $380 to $390 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target indicates that the analyst believes the stock has potential for further growth. This positive outlook could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100